Cellular immunotherapy in breast cancer: The quest for consistent biomarkers

The exploitation of the immune system ’s anti-cancer roles and clinical actionability has opened a new chapter in cancer treatment [1]. Although breast cancer patients are now provided with a variety of therapies, still a fairly high proportion of them experiences resistance or non-responsiveness to pharmacotherapy, including immunoth erapy [2–4]. In this respect, cellular immunotherapy (CI) is emerging as an intriguing field of active research both in translational and clinical settings [5,6]. Despite CI has been initially celebrated in hematologic malignancies and melanoma, several studies have been carried out and are curren tly ongoing in breast cancer patients.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research